Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | USP5 | P45974 | 3/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975803 | 0.92 | EGFR (0.39) | EGFRFGFR1KDRDRD2DRD3 | |
| SCHEMBL977201 | 0.90 | CCR2 (0.40) | EGFRFGFR1KDRSLC6A9SLC6A5 | |
| SCHEMBL3408673 | 0.89 | DRD2 (0.40) | EGFRFGFR1KDRDRD2DRD3 | |
| SCHEMBL977461 | 0.89 | MEN1 (0.44) | EGFRFGFR1KDRSLC6A9LMNA | |
| Hydrochloric Acid SCHEMBL6527164 | 0.88 | DRD2 (0.40) | EGFRFGFR1KDRDRD2DRD3 | |
| SCHEMBL975471 | 0.88 | PTPRC (0.41) | EGFRFGFR1KDRCCR2MEN1 | |
| SCHEMBL3405536 | 0.88 | PRMT5 (0.41) | EGFRFGFR1KDRDRD2DRD3 | |
| SCHEMBL3408729 | 0.87 | EGFR (0.40) | EGFRFGFR1KDRDRD2DRD3 | |
| SCHEMBL977614 | 0.87 | DRD2 (0.39) | EGFRFGFR1KDRDRD2DRD3 | |
| SCHEMBL3406222 | 0.87 | SCN9A (0.47) | EGFRFGFR1KDRDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | claimed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | EGFR 661/4885FGFR1 3835/4885KDR 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.